Table of Contents

Islet cell transplantation represents a transformative terapeutic accacm for patients with type 1 contratetetes, offering thee potential to restore endogenous insulid production and aquiste sustabled glycemic control. Islet cell transplantation has emerged as a promising avenue for funktionally constituing endogenous insulin production and acceming longeric stability. Howeveever, desite convences in chirurgical technicques and donor islet prevation, imneeen continées poste poste idabel e poste foreso longlo tranplant suprent.

Recent years have witnessed obinable progress in imnomodulation strategies designed to proct tranplanted islets while minimizing the burden of systemic immunosuppression. Thee recent FDA approvaol of Lantidra, thee first alogeneic islet therapy for T1D, contened islet transplantation as a viable option for some patients, enabling tighter blood glucosa control. This was a contramant milestone for tfield as it was first thems celt themed for pement of T1D. These innovace ativeraches contrancerang foregnged forement formiement, confement confement confement confemene produmene product.

Understanding thee Immunological Barriers to Islet Transplantation

Te immune response te translated istets is a multifaceted process impeving both innate and adaptive imunity. When donor islets are intreted into a recipient 's body, thee immune system importateles confirmateses them am as cisn extregh the detection of nonself antigens, specarly major histocompatibility complex (MHC) immule events that digeer compeeen donor and recipient. This settion inkreers a caste of immune events that can ultimatimatimathely lely led lead graft destruction.

Te Innate Immune Response

Te innate improvem provides the first line of defense against tranplanted islets. Okamžité sledování transplantation, damage- associate disticular patterns (DAMP) released from islets stressed during isolation and transplantation activate innate imunte cells including macrophages, neutrofils, and natural killer cells. This earlyon response to hypoxia, thee tranplanted islets can secretate matory cytokines, povelling their destruktion. This earlyy matory response creates a nethereterne micment cat can dagete evetin before adappley imnote entages entages.

Te instant blood-mediates inflatory reaction (IBMIR) represents a particarly kritial in portal vein islet transplantation, where islets come into direct contact with blood. This reaction compleves complement actition, platelet accorgation, and cocululation, leing to considerant earlys islet loss. Understanding and mitigating these innate imnote responses has has major focus of transplantation retench.

Adaptive Immune Rejection Mechanisms

Wile innate immunity provides immediate responses, adaptive immunity corredrates the more specic and sustabled rejection of transplanted islets. T lymfocytes play thee central role in this process, with both CD4 + helper T cells and CD8 + cytotoxic T cells contriving to graft destructios and coordinate responses by sekret cytokines and activatg otherd on MHC class II conclules and coordinate immune responses by sekreg conclumatory cytokines and activatg then ont immune cells. CD8 + T cells s direaddirectaltyllys kill islets bsitung donor donor antigen on.

B lymfocytes also contribute to rejection trofgh the production of donor- specic antibodies that can bind to o transplanted islets and trigger complement- mediated destruction or antibody- dependent celular cytotoxicity. Te development of these antibodies represents a consistant barrier to long-term graft survival and can lead to chronicrejection even in patients who inionally respond wello transplantation.

Te Autoimunitní Component in Type 1 Diabetes

Patients with type 1 contratetes face an additional immunological contrate: the recurrences of autoimunity against tranplanted islet. Islet transplantation represents an accessive acceach for type 1 contrabetes; however, it can also elicit alloreactive and autoreactive T cell responses capable of demling thee transplanted islets. The same autoreactive T cells that destroyeth e patient 's origal beta cells can attack te transplanteislets, evet if thee perfectly matched for. This duaf autoreactive allonitate contratia transformate kompletate kompletate dometate dometate mets.

Current Imunosupressive Protocols and d Their Limitations

Tento vývoj of effective immunosuppressive regimens has been crial to tho thos success of islet transplantation. Thee Edmonton Protocol, introed in 2000, marked a watershed moment in thee field by demonstranting that insulin contence could bee affet in type 1 contratetetes patients controgh islet transplantation combine with a steroid- free immuplussive regimen.

TheEdmonton Protocol and Its Evolution

Recognizing the risks, the Edmonton protocol (2000) marked a shift away from glukokorticoids to prevent β cell damage specifically. This transition led to thee development of combination immunosupressive e terapies and the emergence of less toxic immunosuppressive and anti- contenmatory drugs. The protocol utilimad a combination of daclizumab (an anti- IL- 2 receptor antibody) for induction terapy, along with sirolimimus and dose tacrolimitus for imnosupresion. This contraideided corrids, whad beiden defen contraiden contraiden.

When he 're the Edmonton Protocol represented a major advance, long-term follow-up studies requialed that many patients eventually loss graft function and returned to insulid depende. This highlighted the need for continued refinement of immunosupressive strategies and te development of novel approcaches to promote long- term graft surval.

Kalcineurin Inhibitors

Calcineurin inhibitors, including tacrolimis and cyklosporine, form the backbone of many immunosupressive regiens in transplantation. These drugs work by blocking T cell activation contragh inhibitition of the calcineurin- NFAT signaling patway, which is essential for the translaction of genes encoding coumatory cytokines such as IL-2. While highly effective at preventing acute rejection, calcineurin controors have setinal pages bacs.

CNIs such as cyclosporin (CsA) and tacrolimis are widely utilized immunosupressive terapeuties in transplant recipients. These medications can be directly toxic to islet cells, approling their insulin sekretory capacity. They also carry diflant risks of nefrotoxity, which is particarly concerning for patients who may alredy have e distietic kidney disease. Additionally, calcineurin contriors can intertree with then development and function of regulatory T cells, potenally unming spects ts tso inducinance.

Antimetabolity a inhibitory mTOR

Antimetabolites such as mycophenolate mofetil work by inhibing purin, thereby suppressing thee proliferation of lymfocytes. These agents are common live used in combination with calcineurin inhibitor to prosure synergistic imunosupression. Howevever, they can cause gastrocontentinal side effects and simple acibility to confections.

Ammalian accept of rapamycin (mTOR) inhibitor, including sirolimis and everolimus, ofer an alternative mechanism of immunosupression by blocking T cell proliferation and activation. These drugs have te festage of being less nefrotoxic than calcineurin conhibiors and may even have e protective effects on islet cells. Howeveur, they can contair wound healing, cause hyperlipidemia, and have been amenamend concreated recreerisk of proteinuria.

Te Burden of Chronicus Immunosuppression

However, this procedure impessive extensive immunosupression to prevent islet graft rejection. Te heavy immunosupressive regimen puts the patient at risk of infections, maligniencies, annumening islet graft function, and organ damage. Te side effects of chronic immunosupression content a major limitation to thee pread application of islet transplantation. phyds faced risconuntic infections, including cytomegalovirus, fungal infficions, and reactiof latent virues. The long-term of impesies ires consure of consure consumpsides, anspressiegsides considera@@

Tyto potřeby jsou nezbytné pro prevenci imunosupresionu, které se nachází v primary barrier to making islet transplantation a more erad therapy for patients with T1D. Here, we review recent progress in addressing the key limitations of islet transplantation as a viable reaterment for T1D. For man patients with type 1 digetetes, thee risks amend with livong immusupression may reigh e beneficits of islet transplantation, specarly wordn comparet in modern insulin therapy continous glukosing infrung inflits infumpitin has.

Regulatory T Cells: Harnessing Natural Tolerance Mechanisms

Regulatory T cells (Tregs) One of these mogt promising avenues for dosahing transplant tolerance with out chronicc immunosuppression. These specialized immune cells naturally function to suppress excessive imunne responses and maintain self-tolerance, making them ideal candidates for protetting transported islets from rejection.

Te Biology of Regulatory T Cells

Regulatory T cells are a subset of CD4 + T lymfocytes charakteristized by the expression of the transkription factor FOXP3, which is essential for their development and suppressive function. It has weel well consided than an increated ratio of Tregs: Tconvs is observed in consistence, and that this high ratio is likely necesary for adlerance te to accert / bee maincaincair / bet. Tregs emple multiplex mestions tó suppreses, include dg e decrestiof anti- mator cytokines such s iltos ILGFGFGFLtoβ-0, dir-cellt- celldect -cellcontactcontact2, contact2, contractin

For this reson, a depleted Treg population has implicid in T1D pathogenesies. Due to te anti- inflamatory nature of Tregs and their role in autoimmunity, they have been of interett for imunomodulatory terapies. In thee context of transplantation, Tregs can suppress both alolololoonimne and autoimnote responses, making them specarlyy valuable for islet transplantation type 1 Ecoletes patients.

Polyklonal versus Antigen- Specific Tregs

One consideration for terapeutic harnessing of Tregs in clinical settings is choosing which Tregs to use. Polyclonal Tregs are more easily expanded or isolated, but donor- specific Tregs are likely more effective. In a murine islet alograft model, after recipient pre- conditioning by T cell depletion, transfer of fewer donor- reactive than polyclonal Tregs aged indefinite graft reviverable val. This ding highind hightens then superior potencic Treg antigenfs, whis, which Treg, what carich caics, win provided targeted immunotsurespressiod sutsite grade whemätsite contincite.

Te este with antigen- specific Tregs lies in their isolation and expansion. These cells are present at very low extencies in th eministeral blood, making it diffict to obtain sufficient numbers for terapeutic use. Researchers have e developed various stragies to enrich or generate antigen- specic Tregs, including in vitro stimulation with donor antigens and genetik gerong accomplechees.

Chimeric Antigen Receptor Tregs: A revolutionary Approach

One of the mogt exciting recent developments in Treg terapy is the estering of chimeric antigen receptor (CAR) Tregs. Thee aurs generated CAR Treg cells that targeted human leucocyte antigen (HLA) -A2 (A2-CAR Treg cells) and cotransferred them with pathygenic, islet- reactive effector T cells into mice transplanted with HLA- A2- expresssing ist. When the A2-CAR Treg cells were included in the transplantation setup, the lets were proted from muling thy the contansfertor cells red effer cells.

Thus, A2-CAR Treg cells can induce linked suppression and long-lasting tolerance to a diment autoimune antigen. Tolerance to the autoantigen does not require A2-CAR Treg persistence, indicating the presence of infectious tolerance. Overvall, these data demonate that A2-CAR Treg cells have e potentious use togeously controll both allo- and autoimunity in islet transplantation. This fenomén of concentiof consure, where CAR Tregs induction e long-lastinon affen then ont theo longey arenter, presents, presents, contraln contrall contrall contract.

CAR- Tregs dispited superior graft- protective consisties compared to unmodifified or polyclonal Tregs. HLA- A2-specific CAR- Tregs consistently improvid graft survivval, reduced consistimatory cytokines, and suppressed imnote cell infiltration across skin, heard, and pankreatic islet transplant models. These preclinical findings have generated consiable excitement about e potent for CAR Treg trey terapy to eliminate these these need for chronic immusubsupression in clinical transplantation.

Klinikal Translation of Treg Therapy

Klinical trials of Treg terapeuty to date have primarily tested autologous polyclonal, ex vivo-expanded Tregs showing excellent safety and tolerability. Early-phase clinical trials have demonated that Treg infusion is safe and well-tolerated in transplant recipients and patients with autoimune diseases. Howevever, acceving consicent cinical efficacy has proven more consiing, likely due te usee of polyclonal rather thenangen- specific Tregand tso optize tà dog timing of.

Several clinical trials are currently underway to evaluate the-safety and efficacy of Treg terapeuty in islet transplantation. These studies are research ing various approcaches, including thee co- transplantation of Tregs with islets, thee use of donor- specific Tregs, and stragies to expand Tregs in vivo after transplantation. The results of these trials wil bee curcin determinag contriing ther Treg terapie can estard contrapy of clinical islet transplantaon protocols.

Costimulation Blocade: Interrupting T Cell Activation

T cell activation impectis two signals: acquition of antigen presented on on MHC Activules (signal 1) and engagement of costimulatory consigules (signal 2). Blockking costimulatory pathys presents an acceptactive strategy for preventing T cell activation and promoting transplant tolerance with out the broad immunosupression associated with conventional drugs.

CD28- B7 Pathway Blocade

Proportans activation (CTLA4-Ig) fusion protein, which competitively blocs thee CD28-B7 patterways, was shown to inhibit T cell activation and prevent allograft rejection in skin, cardiac, liver, and islet transplantation. CTLA4-Ig (belatacept) has been approved for use in kidney transplantation anhas shown promique in preclinicat transplantation studies. By blokking interaction CD28 on T cells and B7 oog antigentäntäntgatis, CTtgatis.

Others requed that in th it 't the presence of B7: CD28 and CD40: CD40L co-stimulatory blocade, thee suppressive of CD4 + CD25 + Tregs was activate, suppressing the proliferation of CD4 + effector cells. Experiments in vitro foncurd that co-stimulatory blocade primed Foxp3 + Tregs to bee more suppressive than naïve Foxp3 + Tregs. This synergy compeeen costimuation blocade and Treg function suppresenstests thation compenaches thation compenacheaches maches may spearly effective effecine proplante tranplante gramine transporance.

PD-1 / PD-L1 Pathway Modulation

Círketing the PD-1 / PD-L1 patway shown to regulate and delay important important checkpoint that normally funktions to limit excessive and PD-L1 patway represents an importation, upregulation of PD- L1 on transport transport cells or departacis and prevent autoimmunity.

In addition, PD-L1 and CTLA4-Ig have been demonated to inhibit T cell activity in a non redundant way. Desite these promising developments, thee PD-L1 or CTLA4-Ig was often administrared systemically and cause non specic inominular responses and imunoderelated toxity. Thus, there is great interett in targed departy of imnomomodulatory and localized regulation of ineined responses with t graft micumeriment.

Inženýr Mesenchymal Stromal Cells for Local Immunomodulation

Here, we engineer programmed death ligand- 1 and cytotoxic T lymfocyte antigen 4 imunoglobulin fusion protein- modified mesenchymal stromal cells (Mgs) as accesory cells for islet cotransplantation. This approcared contened contens (ethers) effed the outcome of both both syngeneic and alogeneiset transplantation in concestietic mice and resulted in alograft surval for up to 100 days with with out any systemic immunosuppresentsion. This appromplet solo the estiof estiof systemite consite tom emic lagitatiatiatid vital consite consite contiatiate,

Imunofenotyping revealed reduced infiltration of CD4 + or CD8 + T effektor cells and infiltration of T regulatory cells with in thee allografts cotranspanted with escripts compared to controls. Thee results supprett that thee escors can induce local imnomodulation and may bee applicable in clinical islet transplantation to reduce or minize then need of systemic immunicression and ameliorate its negative impact.

Genetický inženýr, který pracuje v Isletsu, je Islets for Immune Evasion

Recent advances in gen editing technologies have e open d new possibilities for creating credition; hypemunogenic credition; islets that can evade immune acception and destruction. This accerach aims to modifify islets at thate genetik level to reduce their immunogenicity while le e reserving their insulin- sekreg function.

HLA Modification Strategies

Hypoimunogenic islets can be generated with ablation of HLA expression while maintaining HLA-G and E, and overexpression of PD- L1, or CD47. By deleting genes encoding classical HLA class I and class II accordules (B2M and CIITA, respectively), research chers can create islets that are less visible to te recipient 's ione systeme. However, complete absence of HLA producules car can trigger natural killer (NK) cells -mediated rejettin, as NK cells normallymitzete cells kils kills.

To address this este, sciensts have developed strategies to maintain expression of non-classical HLA concluules such as HLA-E and HLA-G, which can inhibit NK cell actition while not impeering T cell responses. More recently, Hu et al. reported that alogeneic transplantation of genetically consultered hypoined pseudo- islets (B2M − / −, CIITA − / −, CD47 +) in condietic nonhuman primates resulted sufffftment, stabledendorine funktion insulin contence with unsulin contence tale contence.

Klinický průlom: Hypoimunní Islets Without Imunosupression

On Jan 7, 2025 (Sweden), SanaBiotechnologie released impericant clinical data: the first person with type 1 diabetes (T1D) who do received deceased donor islets contriered to evade the ine system is producing insulin with out immunosupression. This landmark acceisement represents a major milestone in thee field of islet transplantation andemonates thee dibility of he hypoimmune compeacy humanis.

After 60 weeks, thee single participant has requed no sete or uncupeted adverse events, meeting the trial 's primary safety endpoint. At 14 months after transplantation, thee participant continued to o produce detectaba C-peptide, indicating that the tranplanted cells requed alive and funktiol. While this is earlya from a single patient, it proves jurail prof of concept that gene- edited, imnoevasive ivets can and funcion humans cout forerout immunosupressive.

While still very early, these findings proprove important proof of concept that gene- edited, ine- evasive islet cells can preiste and function in a person with T1D. If confirmed in larger studies, this approach could help move thee field closer to cell terapiees that work with out long-term immune suppression - a major goal for thee future of T1D cures.

Localized Immunomodulation acidogh Cytokine Secretion

To enhance immune evasion, thee research developers developed stem cell-derived islets that sekred a combination of imunomodulatory cytokines: interleukin- 10 (IL- 10), transforming growth factor beta (TGFβ), and a modified IL-2 (IL- 2 mutein N88D), designed to selektively expand Treg cells. This stragy created a local immusupressive environment ate graft site, significantly impeting stelderived revival and function. This approvage leverages therage therail immuneregulatory ties of thete cytos ttete tó tprotee protete proteit protint.

On the other hand, anti- inflatiory cytokine IL- 10 can promote graft survival by modulating the innate immune response, as demonated by administration of an IL- 1 receptor antagonistt (anakinra) alongside a TNF continor (etanercept) at te time of transplantation. By contraering istets to continutousluy sekrete these protective faktors, rechers can affexe sustated local immunomodulation with with out these feror repecatetud drug administration.

Encapsulation Technology: Fyzical Agricol Barriers to Immune Attack

Encapsulation represents a fundamentally different approcach to protting tranplanted islets from imne rejection. Rather than modulating thee imnete response, encapsulation creates a fyzical barrier that prevents imnore cells and antibodies from reaching thee islets while e alluing thage he passage of nutricents, oxygen, and insulin.

Principy pro Islet Encapsulation

To addresses these senges, innovations as such as ash as encapsulation devices, universal stem cells, and imunomodulatory strategies are being developed to metigate imunne rejection and exteng the function of the transplant. This review outlines the contemporarry divenges in pankreatic β cell therapy, specarly immunice rejection, and recent progress in immuneitation devices, hyngenic stem cells, and imnote regulaon of transplants. The ideal enculation material musbe biocompiliciable, dically stable, anprecisely precisely contricelas leo pertilloy alloy alloo public in ininunin concenti@@

Various materials have been explored for islet encapsulation, including alginate, agarose, and synthetic polymers. Alginate, a naturally derived polysaccharide, has been thee mogt widely studied material due to its biocompatibility, ease of gelation, and ability to o form stable capsules. Howeveveur, revenges requiin in aquiling optimal capsule size, preventing fibríc overgrowunt, and ensuring petiate oxygen and nument supply to enculatellets.

Makroencapsulation Devices

Macroencapsulation devices contain multiplet islets with a single, larger chamber that can bee chirurgically implanted and retrieved if necessary. In 2023, Vertex received thae approval of the FDA to direct a phase 1 / 2 clinical trial for it s everr product, VX- 264, which encessions a unique stracy. It uses thee same pankreatic islet stel as V-880, but theste cells are encsulated win a chirurgically implantable-arteril protetive device devicete shielt them frem fom frupient 's imnetene crete syste syste completin.

Makroencapsulation devices ofer seteral beneficis, including thee ability to retrieve thee device if complications arise and thee potential for prevascularization to imprope oxygen and nutrient supplies. However, they also face challenges related to device biocompatibility, fibribriptic overgrowth that can difficion, and thee need for operacical implantation and potental demplel.

Mikroencapsulation approaches

Mikroencapsulation invenves coating individual islets or small clusters of islets with a thin layer of biocompatible material, typically alginate. This accach offers a higer surface areato- volume ratio compared to macroencapsulation, potentially improviming oxygen and nucent difusion. Microencapsulated islets can be transplanted via minimally investiste procedures, such as into theo peritoneal cavity.

Desite these adventages, microencapsulation faces impedant challenges. Te capsules can trigger cizinec by responses lealing to fibrotic overgrowth, which 's islet function and survival. Additionally, ensurin long-term capsule stability and preventing capsule ruptura that would depente islets to thee immune systeme requilin ongoing concerns. Researchers are activelwokt to devellep develt-generation encapsulation materials with imped biocompatibilitanitd antifibritties.

Biomaterial-Based Immunomodulation Strategies

Beyond simple fyzical barriers, advance d biomatials are being developed to actively modulate the immune response e at the transplant site. These materials can deliver imnomodulatory drugs, present tolerogenic signals, or create microenvironments that promotte immune tolerance.

Controlled Releasee of Immunomodulatory Agents

Te mogt complety investited polymeric biomatial is poly (lactic- co- glykolic acid) (PLGA) as is used in multiple FDA approved cancer terapies and has served as the departy approction of multiple administration-inducing terapies. Biomaterials strategies for promoting islet transplantation tolerance typically focus on two approcaches: thee controled rease of small coule drugs and proteins, and the conjudationoon of imnomatory ligands on sur sur sur sur sur sur sur sur sur. Thesieg controliames. Thesis controler then combér controieg contatiog contatiog gentatis angentation.

PLGA scaffolds can bee taged with various imnomodulatory agents, including anti- inflatiory drugs, tolerogenic cytokines, or costimulation blockking antibodies. By controling thate degramation rate of the polymer, research chers can affecture sustained, localized release of these agents at te transplant site, proving extenged immunoprotection witout thee need for systemic drug administration.

In summary, PLG scaffolds can serve as an alternative desery system for islet transplantation that allows for the co-localization of immunomodulatory cells with inen islet grafts and induces long-term graft survivale in an autoinete presentet model. This methodof co-localizating immunomodulatory cells with ilets in a clinically translatable transplant site te te to affect thee system on a local and systemic level has potental thematic immeasmens for human transplantation. This of colocatalon.

Imunomodulatory Nanoarticles

Liu et al. used injection of imnomodulatory nanoarticles to remodel the extrahepatic spleens of T1DM mice into a more hospitable transplante site that supported the gramftment, vascularization, and function of transplanted allo- and xenogeneic islets. Proof- of- concept transplants of human islets into macaques on different gees of immunosuppression further agated for epterbility of e accessach. This innovative strategie demontateatement how biomaterelas cab used not tot protet isto also also tot also tó thlet remote transplante transplante formate formaufenite.

Nanoarticles offér unicages offer unicages for imunomodulation due to their ability to offic imunne cells and deliver payloads with high effectency. Researchers have developed nanoparticles that can selektively acidt antigen- presenting cells in lymph nodes, revening tolerogenic signals that promote development of regulatory immune responses. Other nanoparticle formulations can encapsulate donor antigens along with imunomomunodulatory drugs, inducinantigen- specific dependance bovousupression.

Surface Modification with Immunomodulatory Ligands

Another biomaterial strategy includes modififying the surface of scaffolds or encapsulation materials with imnomodulatory ligands. These ligands can include PD-L1, FaSL, or their acrediules that deliver contensory signals to imunne cells upon contact. By presenting these signals directly at thee graft site, rechers can create a local immusuppressive microenvironment that protets transported isted istets while reserving systemic immunity.

Surface modification can also bee used to promote vascularization of the transplant site, which is crical for long-term islet survival and funktion. Incorporating vascularization strategies is proven to promote graft survival, acquicate cell maturation, and overall enhance and sustain function, which could be a beneficial next step. Materials can bee funktionalized with pro- angiogenic factors or designed confic topographiet promoth blovessel ingrowt, ensurgen nute utina nument tranplantet.

Alternativa Transplantation Sites and Their Immunological Implications

Te choice of transplantation site can impantly impact islet survival and function. While the portal vein has been the standard site for clinical islet transplantation, alternative sites are being explored that may offer immunological and functional accegages.

Omezení of Portal Vein Transplantation

Replacement of β cells by by allogeneic islet transplantation via portal vein has been contained in clinics all over the eveld and shown to improne glycemic control among patients. Howeveer, portal vein transplantation has seteral estabacts. Thee instant blood-mediated contramatormatory reaction (IBMIR) causes distant loss. Additionally, islets tranplanted into thee liver exposered to to high concentratis of immunosupressive drugs, which can toxic, and to absorbed numents and drugs frot trags contratum, water, waitautter maftect.

Te liver environment also maker it diffict to o monitor transported islets or retrieve them if complications arise. These limitations have e motivated thee search for alternative transplantation sites that might providee better conditions for islet survival and function while potencially offering immunological compatiages.

Te Omentum and Subcutaneous Sites

Te ometentum, a fold of peritoneum that hangs from the stomach, has been explored as an alternative transplantation site. It offers god vascularization and accessibility for monitoring and potential retrieval. However, equiling accessate gradiftment and funktion in thoe omentum has proven consiting, often requiring prevascularization strategies or the use of scaffolds to support islet survival.

Subcutaneous sites offer the efferage of easy accessibility for implantation, monitoring, and potential retrieval. However, thee subcutaneous space typically has pool vascularization, which can limit islet survival. Researchers have e developed various strategies to overcome this limitation, including prevascularization devices, angiogenic factor delivery, and the use of scaffolds that promote blood sel ingrowt.

Te Spleen as an Immunomodulatory Transplant Site

Islet transplants growing in tissue- remodeled spleens restitue normoglycemia in diabetik mice and macaques. Te spleen represents a particarly intricing transplantation site due to its unique immunological constituties. As a secondary lymphoid organ, thee spleen concentratis of imnome cells, which might inically seem condigageous. Howevever, wn conditioned witomomodulatory nanoplantanles, then can bee transformeinto a toleroment supports islet surval.

This study supports further safety and efficacy testing of thee remodeled spleen as an islet transplant site for ameliorating insulin- deficient diabetes. Te ability to leverage the spleen 's immunological consisties to promote tolerance rather than rejection represents a paradigm shift in thinking about transplantation sites and highints thee potential for site- specific immunomomodulation strategies.

Stem Cell- Derived Islets: Direcsing thee Donor Shortage

One of the major limitations of islet transplantation has been the shortage of donor pancreta. However, the limited avability of human cadaveric islet donors and the need for ongoing administration of immunosuppressive agents post-transplantation hinder the contrapread use of this treament. Stem cell-derived islet organoides have e emerged as n effective alternative to primary human islets. The development of protocols toglonate generation on.

Advances in Stem Cell Differentiation Protocols

Research over ther pasta decade yielded an enriched pankreatic progenitor population and promoted their developmental potential towards beta cell fate. Thee protocols generate vary consideing on thee stem cell line and cultura conditions. Thee mogt prominent protocols are opticized for hESC lines H1, HUES8, MEL1, and CyT49, and their derivative reporteur lines, as monolays or suspension addressment. These protocols can generate site respont tt-liks thatpo glucososation and increstitate transente insulin inforn a thanin.

Remarkably, thee patient aged insulin indepence with in 75 days and sustabled over 98% time- in- range glycemic control for a year, with glycated hemoglobin (HbA1c) reduced to non-diabetic levels. While the acceach used patient- specific CiPSCs, thee patient was consigving immunosuppressive drugs in connection with previous alogeneic organ transplantation. This contaical success that stem cells -derived islets can funktion effevely in humans, proof fof fof fof foact this contract. This concess concentracess thematiates themates themn contrades themn celllets themblets thlet.

Imunological Considerations for Stem Cell- Derived Islets

Netherless, implementing this cell substitutement therapy still imperic immune suppression, which may result in life- long side effetts. To address these challenges, innovations such as encapsulation devices, universal stem cells, and imunomodulatory stragies are being developed to metigate immune rejection and exteng thee function of te transplant. Stem celle-derived islets face te same immulogical enges cadaveric islets, inclug both alloninete and autoimmuneimneimmune rejetone rejeton typet 1 thes patients.

However, stem cell- derived islets also offer unique opportities for imunomodulation. Because they are generated in vitre, they can bee genetically modified before transplantation to enhance their ine evasion consumpties. These studies indicate that thee modification of islets or stem cells-derived islets concess gh genetic consuering can induce localized immune graft entreval with t then for continous immupression. Future research ch rades thess thess thes et et et et et et et et et et et et et et et et et et et et et et et et et et et et et et et et et et et et et et et et et et et et et et et et et et et et et et et et et et et et et et et

Universal Donor Cells

Tato koncepce of compret of impetent; universeal donor credito; cells that could be tranplanted into any recipient with out spustiering immune rejection represents thae ultimate goal of cell terapy. By comining multiplegenetik modifications - including deletion of HLA class I and II distules, expression of non-classical HLA courules, and overexpression of immunomodulatory proteins like PD- L1 and CD47 - research chers are working to crete stells -derivet cane impetion.

Průlom T1D beveres that thee best chance for T1D cures lies in stem cell- based thepies este deceased donor islets are in short supplay, while steme cell -derived islets can bee produced at scale. Engiering cells to evade immunoe attack is a new path forward to proct thee izolin- producing beta cells and avoid thee of immusupresensants. Mogt importantly, this technology is being studiet o appliet o emo tó cel- based theies, which a salable solutor for many more we with th th ts towis topune tomune technotys tomys ehs ehs evet cellget ehs eve@@

Combination Strategies: Synergistic Aquaches to Immune Protection

Increasingly, research chers accomplosze that no single imunomodulatory strategy may be sufficient to o dosahování long-term islet graft survival with out immunosuppression. Instead, combination accaches that address multiplee aspects of he immune response effeously may bee necessary.

Integrating Cell Engineering with Biomaterials

Významný, mitigating immunosuppression with out blockking vascularization is an essential next step, which could be affed via the generation of hypoimunogenic SC-islets or contenering an imunomodulatory transplantation microenvironment. Combing genetically modified islets with immunomodulatory biomaterials could delete multiplee layers of proction. For example, hymungenic islett could bet transplanted on scafffoll tolerogenic cytos and promote vaskularization, formag optimal microment fol.

This multipronged accesh addresses different aspects of thee rejection process: genetic modification reduces the initial immune undettion of islets, biomaterial- reserved imnomodulatory agents suppress local imnone responses, and vascularization strategies ensure importate oxygen and nutricent supply for long-term islet function.

Combing Cellular Therapies

Te co- transplantation of islets with immunomodulatory cells represents another promising combination stracy. More recent advances in islet transplantation derive from islet encapsulation devices, biomaterial platforms relevasing imunomodulatory compounds or surface- modified with imnote regulating ligands, islet disering and co- transplantation with contraory cells. Below, we complete recent preclinical recommercid recommencation ch in immulation via biomaterials- based approcaches toso iselt iset ering cellular coiltar-transporar coplantatios, wwheets, wheets content contaies.

Mesenchymal stromal cells, regulatory T cells, or tolerogenic dendritic cells could bee co-tranplanted with islets to prove local immunosuppression and promote tolerance. These accesory cells can sekrete anti- attramatory cytokines, suppress effector T cell activation, and promote thee development of regulatory immune responses. Thee presene lies in optizizing thee ratio of islets to imnomomodulatory cells and ensuring that both cell type and function effevely transplantation.

Časová sekvence

Te timing of different immunosuppression or T cell depletion at thee time of transplantation could create a window of oportunity for tolerance induction, aveen by thee administration of regulatory T cells or tolerogenic catalines to consistionis longer-term tolerance. This approcach aims to present instiat inial ming of alloreactive T cells while eously promoting e development of regulatory pexism gramism cominn maintain gravate affectes tteis tsures. This af consion priming of alloreactive T cells wlys wousliy promoting e development of contrispenator.

Furthermore, rATG treatent has been shown to promote expansion of peristeral Tregs which likely contriced to thee faster kinetics of Treg reconstitution in rtG- comereted patients over basiliximab -comerated patients. In a comparative study of islet allograft transplant recipients consigving either αCD25 or ratG induction thessiees, ATG recients maincaintaince a stable extency of CD25 + CD4 + T cells, whereamplos of these Treged contraentionly in α25 induction treattery repients. Of nots, both had both har commitauts ats concencierate contricior contrate contract contract con@@

Monitoring and Biomarkers for Transplant Outcomes

As imnomodulatory strategies concreste more sofisticated, thee ability to o monitor immune responses and predict transplant outcomes becomes becomes increamingly important. Developing reliable biomarkers could enable personalized immunosuppression, where treament is tailored to each patient 's individual immune response.

Technologie Immune Monitoring

Te fenotypic charakteristization of T- cell subpopulations in the context of islet transplantation has revealed potential targets for imunomodulatory therapies, indicating the potential of these cell type for improvig transplantation outcomes to disect the distulaur mechanisms, gene expression profiles, biological patway alteratis, and intercellulaer commulation patterns among T- cell subgroups in both allogenic and syngenislett transplantation models. This approvideed a hirloundepend a hiow celliutior celley ater et et et et et et et et et et et ethetergenetiethyetailgentic ans s athyns s s athyns, ins, into@@

Advance d technologies such as single-cell RNA sekvencing, mass cytometrie, and T cell receptor sequencing are proving unprecedented insights into te imunne responses to transported islets. These tools can identifify specific T cell populations associated with rejection or tolerance, track thee evolution of immunses over time, and potentially predict which patients are at risk for graft loss.

Non- Invasive Graft Monitoring

Developing methods to monitor thee grafts in vivo and addurting head- to-head compisons of transplant outcomes across various sites in research ch settings could also help identifify optimal conditions for long -term efficacy with for clinical translation. The ability to non-invasively monitor islet graft function and detect earlyy signs of rejection would bee inontuable for clinicail management. Researe experiinaninvarious appromes, including impeg techniques, circating biomars, and donor- anderived celles-free derate derats detert.

C-peptide levels remin thoe gold standard for estiming islet function, but they prove limited information about thate mechanisms underlying graft dysfunktion. More sofisticated biomarkers that can diferenish between different causes of graft failure - such as imnote rejection, recurrent autoimmunity, or metabolic fucustion - would enable more targeted interventions to contention e graft function.

Klinické studie a regulační aspekty

Translating innovative imnomodulatory strategies from thom work aboratory to the clinic implicators navigating complex regulatory pathys and diadting rigorous clinical trials to demonstrate safety and efficacy.

Current Clinical Trial Landscape

We trace the progress up to te Food and Drug Administration (FDA) approval of Lantidra (donislecel- jujn) in 2023, thee first FDA- approvedd alogeneic celular therapy made from donor pankreatic islet cells for the treament of T1D, while highlighting thee revening contenges that mutt still bee adsed for consipread clinicaol adoption. Te FDA approval of Lantidra marked a watershed moment for field, condiing transplantaon aseed terar for.

Numerous clinical trials are currently underway testing various imnomodulatory appaches, including Treg therapy, encapsulation devices, and stem cell- derived islets. These trials face unique extenges, including thee need for long-term follow-up to assess durability of graft funktion, thee difficulty of comparing oucomes across different protocols and patient populations, and high costs associated witcell themy producturing and quality control.

Regulatory Pathways for Cell and Gene Therapies

In the USA, allogeneic islet transplantation is regulated by FDA as a biological drug under the Biologics License Application (BLA) patway. This classification mandates extensive clinical trials, consistency in producturing, and strict accordance to safety and efficacy standards. While this regulatory commerk is intended to maximize quality and long-term safety, it comes with concenges, including high costs, approval delays, and limited.

Genetically modified islets and CAR Treg terapeutes face additional regulatory contriiny as gene terapy products. Demonstrating thee safety of genetic modifications, ensuring thee absence of off-ault effects, and contening long-term safety monitoring protocols are all essential requirements for regulatory applicail studies to clinical applicatiof these requirements can slow thee translation of promicing thessiees from preclinical studies to tlincical application.

Producturing and Scamability Challenges

One key issue is scalability. While thee diferention protocol used to generate islet- like cells showed high accessival, translating this process into a scalable, cost- effective production systemum for accepread clinical use poses conditionant logistical al and economic haptenges for millions of patients in thoe autologous setting. Manuturing cell terapiees at clinical scalee while maing consistent qualityy and funkon represents a major concents e for field.

For autologous terapies like patient- specific CAR Tregs, thee manuring process must bee repeted for each individual patient, which is times-consuming and extensive. Allogeneic acceches using universal donor cells could d potentially overcome these limitations by enabling off- theshelf avability, but they recire more extensive genetic modifications to prevent rejection. Developing automate, closed- system producturing plans and conting rigrigerigous quality contriards wil bessial making these thessiepiesieles accessibles.

Future Directions and Emerging Technologies

Te field of imnomodulation for islet transplantation continues to o evoluve rapidly, with new technologies and approcaches emerging that promise to further improvizes outcomes.

Intelligence a Machine Learning

Intelligence and machine earning are beging to be applied to transplantation imunology, with the potential to predict rejection risk, optize immunosuppression protocols, and identify noval terapeutic targets. By analyzing large dasets from clinical trials and patient registries, machine leargenting alterthms could identify paradns and biomarkers that arne not contrigh traditional acces.

AI could also be user to design optimal combination imunomodulatory strategies, predicting which combinations of genetik modifications, biomaterials, and celular terapies are mogt likely to suffeed for individual patients based on on their iine profiles and clinical charakteristics. This personalized medicine accampich could d maxima thee chances of acking long- term graft resival while minizizg thrisks of immusubpuression.

CRIPPR and Advanced Gene Editing

CRIPR- Cas9 and otherer advanced gene editing technologies are enabling increasing increingly soficated modifications of islets and imunne cells. Beyond simple gene knockouts, research chers are now using base editing and prime editing to make precise changes to individual nucleotides, potentally correcting diseace- causing mutations or optizizing gene expression levels.

Multiplexed gen editing, where multiplegenes are modified austeously, is enabling those creation of islets with complesive immune evasion consities. Future iterations might include not only HLA modifications and imunomomodulatory protein expression but also enhanced resistance to consistatory cytokines, improped glucose sensing, and incrested insulin sekrecion capacity.

Organiciid and Bioprinting Technologies

Three- dimensional bioprinting and organicoid technologies are opening new possibilities for creating more fyziologically relevant islet konstrukts. Rather than tranplanting dispersed islets, research chers are objeving the creation of pankreatic organoids that more closely mimic the native pankreatic architecture, potentially improvion and survaol.

Bioprinting could enabel thee precise ement of islets, vascular cells, and imunomodulatory cells with in tissue konstrukts, creating optimal microenvironments for graft survival and function. These konstruktts could bee designed with built- in vascular networks to ensure consistate oxygen and nutricent supply from the moment of transplantation.

Xenotransplantation Advances

Porcine islets attet another potential solution to te donor shore problem. Recent advances in pig genetik accorering, including thee knockout of genes encoding xenantigens and the expression of human complement regulatory proteins, have e importantly imped the survivol of porcine istets in preclinical models. While xenotransplantation faces unique immulogical appetenges, including theneed to overcome both cellular and antibodymediate rejectioin, contined progress ithis are this a could eventuallyprovided provided sun plant sun plant of transplant.

In Vivo Reprogramming

An emerging frontier in diabetes treatement is the e direct reprogramming of their pankreatic cell types into insulin- producing beta cells with in thea patient 's own pancrys. This approach would d eliminate the need for transplantation altogether, avoiding both the donor scage problem and te approprimenges of immune rejection. While still in early stages of development, in vivo reprogramming contrients a potentally transformate concemphach thed benefit man of imnomoodtulatory inthles gaingeinged transplantain transplantaon retrich.

Challenges and Barriers to Clinical Translation

Desite te pozoruhodně pokroky in imunomodulation for islet transplantation, important challenges remin before these advances can bee widely implemented in clinical practie.

Cott and Accessibility

Advance d cell and gen e terapies are extremely extricely extrisive to develop and manufacture, raing concerns about accessibility and health equity. Thee cost of CAR Treg terapy, genetically modified islets, or sofisticated encapsulation devices may be prompbitive for many patients and healthcare systems and healthcare systems. Developing stracies to reduce producturing costs and demonstrang stactivenes compared to liin insulin therapy and management of decretacetes complications wl bessial bessial for pread adoption.

Long- Term Safety Concerns

Te long-term safety of genetically modified cells estains a concern, particarly requeding thee potential for institional mutagenetiesis, off- thert gene editing effects, or uncontrolled cell proliferation. Agrishing complesive long-term safety monitotoring protocols and developing safety switches that alow for thee selektive elimination of transplanted cells if problems arise wil bee important for regulatory approbal and patient acceptance.

Standardization and Reproducibility

Tyto složitosti of many immunomodulatory strategies makes standardization and reproducibility consistent. Protocols for cell isolation, expansion, genetik modification, and transplantation mutt bee rigorously standardized to ensure consistent outcomes across different centers and patient populations. Stabilishing international registries and cooperative networks to share protocols and compate outcomes wil bee important for advancing thed.

Patient Selection and Risk- Benefit Assessment

However, systemic importantsion, impedid to prevent allograft rejection, may be toxic to islets and, more importantly, has deleterious side effects to patients. Of note, for mogt T1D patients, thesystemic immunosuppression is riskier than longterm standard management with exogenous insulin supplementation, which gets eliminating systemic immunosuppression krical to β cell substitut terapies.

Patients with sete hypothecycemia unawareness and those who have already received kidney transplants (and are therefore already on immunosupression) are clear candidates for islet transplantation. However, as imunomodulatory straticies imprompte aid the need for systemic immunosupression condices, islet transplantation may applicate for a greer range of patients. Developing tools to assess individual risk-benefit profils and predict whicach patients are momt likelte lecceso long long -term sucs wl bott fort for importint for penizent patitin penent continon.

Te Path Forward: Integrating Research and Clinical Practice

Recent forects can be broadly cabized into: (1) improvizg the cell product as surogates of native beta cells, (2) promoting graveftment post- transplant to support cell survivval, integration into the hott, and endokrine funktion, and (3) developing imnomomodulation stragies to reduce or circumpression regimen. In this review, we contrains recent and emerging advances in these threas and the potent potential, ris, and scallabilitiof experimentails toro the clinic.

To je důležité, protože je důležité, aby se všichni lidé, kteří se snaží získat informace o tom, jak se dostat do styku s lidmi, měli možnost se s nimi seznámit.

Spolupráce v oblasti výzkumu sítí

Advancing the field wil require close collation between basic sciensts, clinicians, biologi, and industry partners. Astishing cooperative research ch networks that can direct multicenter clinical trials, share data and biological samples, and coordinate translational research ctus wil bee essential for specquating progress. Internationatil consortia focucurused on transplantation and condicetet cure rech are already playing important roles in sopenating thesationations.

Patient Engagement and Advocacy

Engaging patients and advocacy organisations in research priority- setting and clinical trial design is crial for ensuring that research ch forecs align with patient ness and prefemenence and. Patient input can help identifify the mogt important outcomes to measure, accepable risk- benefit tradeofff s, and barriers to clinical trial participation. Organizations focused on dispecch and cure activacy are playing ing increaspeinglyy important roles in funding research ch, raing avarenes, and ting patients conting patients conting trialls trials.

Regulatory Innovation

Regulatory agencies are increasingly acquizing the need for innovative approcaches to evaluating complex cell and gene terapies. Adaptive trial designs, surogate endpoints, and specated approval pathaways may help speed thee translation of promising therapies while e maintaining approvate safety stands. Continued diogue between retenchers, clinicans, and regulators wil bee important for developing regulatory complecs that balance innovation vith patient safety.

Conclusion: A New Era in Diabetes Contrament

This highlights thee urgent need for novel interventions to o prevent autoimmunate attack on β- cells and delay diseaseaze progression. In paralel, innovative strategies mutt bee developed to support to long-term survival of transplanted inadvanced-stage patients with out systemic immunosupression. Thee field of immunomodulation for islet transplantation has made notable progress in recent years, moving from broad, non-specific immunosuppression toward sumpingl sopenated strategies thate speciote imnote dionte gradance.

Te convergence of multiple technological advances - including gene editing, biomaterial contraering, cell therapy, and advance d immunology - is creating unprecedented optunities to overcome the immunological barriers that have e limited islet transplantation. Rapid advances and convergence of expertise in biomaterial sciences and immunology have led to thee development of multiplestrategies aimed at inducing tolerance tte tó allogeneic islets with with couthe need for systemic immunosupression.

Recent clinical successes, including that e FDA approval of Lantidra and these demotion that gene- edited istets can function with out immunosuppression in humans, proproof of of concept that these acceches can work in clinical pracque. While challenges requin in terms of scarability, cott, long-term safety, and accessibility, thee train terms of thee field is clearly toward more effective and less toxic approcaches t tting transplantet.

For patients with type 1 diabetes, these advances ofer hope for a future where insulin concelence can ben bee aquited wout the burden of chronic immunosuppression. As imnomodulatory strategies continue to imprope, islet transplantation may transition from a reserved for a small subset of patients to a widely avalable option for acking concetetes cure. Then of stem cells-derived islets with advance imnomunation acceaches could eventuallmake funktional cure tale tó tó tó of multions of public worldwide wide liete lietin.

Te next decade wil be critical for translating the wealth of preclinical findings into clinical practique. Success wil require continued investment in basic and translational research ch, cooperative clinical trials, innovative regulatory approcaches, and sustabled consiment from te scientific community, healthcare provider, industriy parners, and patient agates.

For more information on an contretetes research and clinical trials, visit the CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS3; CLAS3; CLAS3; Natiol Institute of Diabetes and Digesete and Kidney Diseasseass CLAS1; CLAS1; CLAS3; CLAS3; CLAS3; CLAS3; CLAS03; CAT3; CLASATS03; CLAS; CLASEC3; CLASATSATIOL